Matches in SemOpenAlex for { <https://semopenalex.org/work/W3147885875> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- W3147885875 abstract "Objective To determine the antiplatelet and antithrombotic efficacies of MV1 serine protease on coronary arterial thrombosis in a canine model of unstable angina.Methods Pentobarbital-anesthetized Beagles(total of 30)were used in which acute damage of the proximal left circumflex coronary artery,together with mechanical stenosis,produced the phenomenon of cyclic flow reduction(CFR)in the Folts model of unstable angina.When the platelet plug was removed by rubbing the vessel,the occlusion returned reproducibly for at least 3 hours in control studies.To evaluate the antithrombotic efficacy of MV1,CFR was first established over a period of one hour,thereafter,MV1(0.3,0.6 mg·kg-1 i.v.bolus),Batroxobin(0.3 BU·kg-1 i.v.bolus),Tirofiban(40 μg·kg-1,i.v.bolus),or vehicle was administered and observations continued for two additional hours.Platelet aggregation induced by adenosine diphosphate(ADP),arachidonic acid(AA),collagen(CG)was measured by the method of born,and thrombin time(TT),prothrombin time(PT),activated partial thromboplastin time(APTT)and fibrinogen(Fbg)were measured using coagulation methods,bleeding time was measured according to previous described methods.Results MV1 dramatically inhibited the frequency of CFR dose-dependently and the frequency of CFR decreased by 65%,80% respectively at 1 h than that in control group's after MV1 0.3,0.6 mg·kg-1 administration,further more the frequency decreased by 75%,90% respectively at 2 h.MV1 eliminated thrombus formation in 5 of 6 dogs at 0.6 mg·kg-1,and the time for CFR absolute disappearances of MV1 at a dose of 0.6 mg·kg-1 was shortened to 5±2 min(the time was more than 120 min in all dogs of control group).Platelet aggregation induced by ADP,AA,CG was inhibited effectively by MV1 0.3,0.6 mg·kg-1 TT,PT prolonged gently after MV1 administration,and MV1 produced an approximate 40% degradation of Fbg,but MV1 did not have any effects on APTT.There was a tendency for prolonged bleeding time with MV1 administration.Conclusions These studies showed that as a novel serine protease,MV1 provides favorable antithrombotic activity in vivo with inhibition of platelet aggregation and fibrinogenolytic activity.The results indicated that MV1 has reliable therapeutical efficacy on unstable angina pectoris." @default.
- W3147885875 created "2021-04-13" @default.
- W3147885875 creator A5067425367 @default.
- W3147885875 date "2008-01-01" @default.
- W3147885875 modified "2023-09-23" @default.
- W3147885875 title "Antithrombotic efficacy of MV1 serine protease in a canine model of unstable angina" @default.
- W3147885875 hasPublicationYear "2008" @default.
- W3147885875 type Work @default.
- W3147885875 sameAs 3147885875 @default.
- W3147885875 citedByCount "0" @default.
- W3147885875 crossrefType "journal-article" @default.
- W3147885875 hasAuthorship W3147885875A5067425367 @default.
- W3147885875 hasConcept C126322002 @default.
- W3147885875 hasConcept C164705383 @default.
- W3147885875 hasConcept C185592680 @default.
- W3147885875 hasConcept C2777785093 @default.
- W3147885875 hasConcept C42219234 @default.
- W3147885875 hasConcept C43376680 @default.
- W3147885875 hasConcept C500558357 @default.
- W3147885875 hasConcept C71924100 @default.
- W3147885875 hasConcept C98274493 @default.
- W3147885875 hasConceptScore W3147885875C126322002 @default.
- W3147885875 hasConceptScore W3147885875C164705383 @default.
- W3147885875 hasConceptScore W3147885875C185592680 @default.
- W3147885875 hasConceptScore W3147885875C2777785093 @default.
- W3147885875 hasConceptScore W3147885875C42219234 @default.
- W3147885875 hasConceptScore W3147885875C43376680 @default.
- W3147885875 hasConceptScore W3147885875C500558357 @default.
- W3147885875 hasConceptScore W3147885875C71924100 @default.
- W3147885875 hasConceptScore W3147885875C98274493 @default.
- W3147885875 hasLocation W31478858751 @default.
- W3147885875 hasOpenAccess W3147885875 @default.
- W3147885875 hasPrimaryLocation W31478858751 @default.
- W3147885875 hasRelatedWork W1834486813 @default.
- W3147885875 hasRelatedWork W1988504835 @default.
- W3147885875 hasRelatedWork W2000469492 @default.
- W3147885875 hasRelatedWork W2018279119 @default.
- W3147885875 hasRelatedWork W2036712889 @default.
- W3147885875 hasRelatedWork W2040073678 @default.
- W3147885875 hasRelatedWork W2051221562 @default.
- W3147885875 hasRelatedWork W2087180312 @default.
- W3147885875 hasRelatedWork W2113613986 @default.
- W3147885875 hasRelatedWork W2125810010 @default.
- W3147885875 hasRelatedWork W2243316889 @default.
- W3147885875 hasRelatedWork W2256996510 @default.
- W3147885875 hasRelatedWork W2273506642 @default.
- W3147885875 hasRelatedWork W2323569149 @default.
- W3147885875 hasRelatedWork W2357466513 @default.
- W3147885875 hasRelatedWork W2372077586 @default.
- W3147885875 hasRelatedWork W2394014326 @default.
- W3147885875 hasRelatedWork W2554132186 @default.
- W3147885875 hasRelatedWork W2609520902 @default.
- W3147885875 hasRelatedWork W3212181059 @default.
- W3147885875 isParatext "false" @default.
- W3147885875 isRetracted "false" @default.
- W3147885875 magId "3147885875" @default.
- W3147885875 workType "article" @default.